Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

MDT associated with improved progression-free, radiographic progression-free, castration resistance-free survival.

SAN FRANCISCO -- Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival (PFS) versus a single drug, a large randomized trial showed.

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab ...

Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate ...

Tagrisso plus chemotherapy improved progression-free survival in EGFR-positive NSCLC patients compared to placebo plus chemotherapy, with median survival of 8.4 vs. 4.4 months. Central nervous system ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had ...